Treatment of Cardiac Glycoside Toxicity with Ventricular Fibrillation or Other Life-Threatening Presentation
This protocol applies to patients presenting with signs of life-threatening digoxin toxicity who are not in cardiac arrest — a distinct clinical situation requiring immediate, targeted management.
Clinical Scenario
Life-threatening toxicity is indicated by any of the following:
- Ventricular tachycardia or ventricular fibrillation
- Asystole or symptomatic high-degree atrioventricular block
- Severe hyperkalemia (serum potassium >6.5 mmol/L)
- Hypotension (systolic blood pressure <100 mmHg) with evidence of end-organ dysfunction
Treatment Approach
Management involves prompt administration of digoxin immune Fab, a specific antidote, directed at neutralising toxicity. The complete regimen — including sequencing, escalation criteria, and the basis for dose selection — is available in the full structured protocol.
Full dosing algorithm not shown here — access the complete evidence-based protocol below.
Monitoring Goals
Following treatment with digoxin immune Fab, patients require close monitoring until normalisation of serum potassium, blood pressure, body temperature, ECG findings, and renal function. Serum potassium warrants particular attention during the initial hours after administration.
References
DOI: 10.1097/MEJ.0000000000001065
- Ventricular tachycardia or fibrillation
- Asystole or symptomatic, high-degree atrioventricular block
- Severe hyperkalaemia (serum potassium >6.5 mmol/L)
- Hypotension (systolic blood pressure <100 mmHg) associated with end-organ dysfunction
- For all other cases of life-threatening digoxin toxicity (i.e. patients not in cardiac arrest), an initial dose of 1–2 vials should be sufficient for neutralisation of digoxin toxicity in most cases, and can be followed with incremental doses of 1–2 vials, until resolution of toxicity.
- For other cases of life-threatening digoxin toxicity, an initial dose of 1–2 vials may be administered immediately and repeated based on clinical response.
- Patients should be monitored closely after administration of digoxin immune Fab, including assessment of serum potassium concentrations, body temperature, blood pressure, ECG and renal function (serum urea and creatinine and estimated glomerular filtration rate); monitoring should continue until potassium concentration, ECG and renal function are 'normalised'.
- Potassium levels should be assessed regularly, particularly during the first 6 h following treatment.
View source ↗